Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2007 2
2010 1
2011 1
2012 3
2013 2
2014 5
2015 3
2016 2
2017 6
2018 5
2019 2
2020 5
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. Baccarani M, et al. Among authors: steegmann jl. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Blood. 2013. PMID: 23803709 Free PMC article. Review.
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Mosquera-Orgueira A, Pérez-Encinas M, Hernández-Sánchez A, González-Martínez T, Arellano-Rodrigo E, Martínez-Elicegui J, Villaverde-Ramiro Á, Raya JM, Ayala R, Ferrer-Marín F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vázquez MI, García-Fortes M, Angona A, Cuevas B, Senín MA, Ramírez-Payer A, Ramírez MJ, Pérez-López R, González de Villambrosía S, Martínez-Valverde C, Gómez-Casares MT, García-Hernández C, Gasior M, Bellosillo B, Steegmann JL, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC. Mosquera-Orgueira A, et al. Among authors: steegmann jl. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan. Hemasphere. 2022. PMID: 36570691 Free PMC article.
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Guilhot J, et al. Among authors: steegmann jl. Blood. 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. Epub 2012 Apr 16. Blood. 2012. PMID: 22508936 Free article.
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Hernández-Boluda JC, et al. Among authors: steegmann jl. Br J Haematol. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. Epub 2022 Sep 12. Br J Haematol. 2022. PMID: 36089912
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
Ottmann OG, Stegelmann F, Breccia M, Steegmann JL, Olavarria E, Aimone P, Lipton JH. Ottmann OG, et al. Among authors: steegmann jl. Leuk Lymphoma. 2021 Mar;62(3):739-742. doi: 10.1080/10428194.2020.1839649. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153366 Clinical Trial. No abstract available.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). García-Gutiérrez V, et al. Among authors: steegmann jl. Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Ann Hematol. 2019. PMID: 30446802 Clinical Trial.
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M. Vigón L, et al. Among authors: steegmann jl. Biochem Pharmacol. 2020 Dec;182:114203. doi: 10.1016/j.bcp.2020.114203. Epub 2020 Aug 20. Biochem Pharmacol. 2020. PMID: 32828803 Free PMC article.
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Pérez-Lamas L, de Paz Arias R, Díaz RMA, Montero LFC, Payer ÁR, Sierra M, Marín FF, López RP, Cirici BX, Steegmann JL, Gómez Casares MT, Martínez-López J, García-Gutiérrez V. Pérez-Lamas L, et al. Among authors: steegmann jl. Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662-7. Online ahead of print. Ann Hematol. 2024. PMID: 38568260
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
Vigón L, Luna A, Galán M, Rodríguez-Mora S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José E, Rivera-Torres J, Steegmann JL, de Ory F, Pérez-Olmeda M, Alcamí J, Planelles V, López-Huertas MR, García-Gutiérrez V, Coiras M. Vigón L, et al. Among authors: steegmann jl. J Clin Med. 2020 Dec 25;10(1):42. doi: 10.3390/jcm10010042. J Clin Med. 2020. PMID: 33375572 Free PMC article.
40 results